Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Population-based Assessment of Curative Intended Multimodal Treatment in Patients With Oligometastatic Pancreatic Cancer, Responsive to Neoadjuvant Chemotherapy - ScanPan 1 - A Scandinavian Prospective Multicenter Study

NCT05271110 is registered in ClinicalTrials.gov with Linkoeping University as lead sponsor.

NCT NCT05271110
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05271110 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Population-based Assessment of Curative Intended Multimodal Treatment in Patients With Oligometastatic Pancreatic Cancer, Responsive to Neoadjuvant Chemotherapy - ScanPan 1 - A Scandinavian Prospective Multicenter Study
Lead sponsor
Linkoeping University
Phase
Not applicable
Overall status
Not yet recruiting
Start date
March 31, 2022
Completion date
March 31, 2027
Enrollment
64 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

disseminated pancreatic cancer